A multicenter, open-label Phase 1 study to evaluate the safety, biomarkers and pharmacokinetic (PK), pharmacodynamic (PD) and preliminary clinical activity of AB521 as a monotherapy for advanced solid tumor malignancies (dose escalation) and clear cell renal cell carcinoma (dose expansion).
Key Eligibility Criteria
- Male or female participants over 18 years old.
- At least one measurable lesion per RECIST guidance.
- Disease-specific inclusion criteria for dose escalation: Any pathologically confirmed solid tumor type where no other treatment options are available.
- Disease-specific inclusion criteria for dose expansion: Histologically confirmed ccRCC; prior treatment in the metastatic setting (either individually or in combination) with an anti-PD-1 therapy and a tyrosine kinase inhibitor; and no prior treatment with a HIF-2α-targeted therapy.